Last reviewed · How we verify
Meningococcal C conjugate vaccine
The Meningococcal C conjugate vaccine, marketed by Novartis, holds a significant position in the prevention of meningococcal disease caused by Neisseria meningitidis serogroup C. A key strength is its well-established market presence, supported by a key composition patent that expires in 2028. The primary risk is the potential increase in competition as the patent approaches expiration.
At a glance
| Generic name | Meningococcal C conjugate vaccine |
|---|---|
| Also known as | Menjugate |
| Sponsor | Novartis |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) (PHASE4)
- Long-Term PF-06651600 for the Treatment of Alopecia Areata (PHASE3)
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants (PHASE2)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children (PHASE2)
- Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug (PHASE3)
- MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults (PHASE4)
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meningococcal C conjugate vaccine CI brief — competitive landscape report
- Meningococcal C conjugate vaccine updates RSS · CI watch RSS
- Novartis portfolio CI